Results 101 to 110 of about 1,816 (199)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies

Drug Design, Development and Therapy, 2023
Yusuf Mushtaq,1,* Maryam M Mushtaq,2,* Zisis Gatzioufas,3 Matteo Ripa,4 Lorenzo Motta,5 Georgios D Panos1 1Department of Ophthalmology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust & School of Medicine, University of ...
Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD   +5 more
doaj  

Use of flucinolone acetonide for patients with diabetic macular oedema:patient selection criteria and early outcomes in real world setting [PDF]

, 2016
Introduction: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies.
Ajay Bhatnagar, Andrej Kidess, CS Brand, D Boyer, DM Brown, DS Boyer, DS Levin, E Chew, Fahad Quhill, Ibrahim Elaraoud, JA Wells, JW Yau, Marie Tsaloumas, MJ Elman, NZ Gregori, PA Campochiaro, PA1 Campochiaro, Walter Andreatta, Yit Yang   +18 more
core   +1 more source

A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND) [PDF]

, 2017
PURPOSE: The aim of this study was to assess the effectiveness and safety of ILUVIEN® in patients with chronic diabetic macular edema (DME) who were insufficiently responsive to prior therapies.
Alves, D, Amaro, M, Cunha-Vaz, J, Figueira, J, Henriques, J, Rosas, V   +5 more
core   +2 more sources

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)

International Medical Case Reports Journal, 2020
Bernardete Pessoa,1,2 João Melo-Beirão,1,2 Angelina Meireles,1,2 Pedro Menéres1,2 1Ophtalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Unit for Multidisciplinary Research in Biomedicine ...
Pessoa B, Melo-Beirão J, Meireles A, Menéres P   +3 more
doaj  

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes [PDF]

, 2019
Purpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.
Coelho, João, Malheiro, Luisa, Meireles, Angelina, Melo Beirão, João, Pessoa, Bernardete   +4 more
core   +1 more source

Migration of a Fluocinolone Acetonide Intravitreal Implant Into the Anterior Chamber

JAMA Ophthalmology, 2020
Li, Angela S., Nguyen, Huy V., Do, Diana V.   +2 more
openaire   +2 more sources

Association between visual function response and reduction of inflammation in noninfectious uveitis of the posterior segment [PDF]

, 2017
PURPOSE. To examine the association between visual function response (VFR) and inflammation reduction in active noninfectious uveitis of the posterior segment (NIU-PS). METHODS.
Bodaghi, Bahram, Duchateau, Luc, Lescrauwaet, Benedicte, Miserocchi, Elisabetta, Srivastava, Sunil, Thurau, Stephan, Verstraeten, Thomas   +6 more
core   +3 more sources

Use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity. [PDF]

Digit J Ophthalmol, 2022
Chang PY.
europepmc   +1 more source

Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study. [PDF]

Int Ophthalmol, 2023
Ruiz-Moreno JM, Adán A, Lafuente M, Asencio Durán M, Arias Barquet L, García Layana A, Araiz Iribarren J.   +6 more
europepmc   +1 more source

A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Clinical Ophthalmology, 2015
Vera K Schmit-Eilenberger Augenklinik Städtisches Klinikum, Karlsruhe, Baden-Württemberg, Germany Background: Iluvien® is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 µg/d fluocinolone acetonide [FAc ...
Schmit-Eilenberger VK
doaj